WARSAW, Ind.--(BUSINESS WIRE)--Biomet Sports Medicine, LLC, a subsidiary of Biomet, Inc., announced today the launch of the JuggerKnotless Soft Anchor device. The JuggerKnotless Soft Anchor is the latest product offering in the JuggerKnot Soft Anchor family of all-suture implants, securing its position as a leader in all-suture anchor technology.
This product, which may be utilized for labral repair surgery in the shoulder, is the first all-suture, knotless device on the market. Knotless anchor technology, which allows surgeons to secure soft tissue without the use of surgical knots, represents a large and growing segment of the sports medicine shoulder market. By combining all-suture and knotless technologies, Biomet Sports Medicine is creating a new market segment, as it did four years ago with the launch of the JuggerKnot Soft Anchor Device.
“Biomet has a strong and proven tradition of developing state-of-the-art products like the JuggerKnot Soft Anchor,” says Dean Trippiedi, Vice President and General Manager of Biomet Sports Medicine. “The JuggerKnotless builds on this tradition by bringing together Biomet Sports Medicine’s all-suture and adjustable loop technologies to provide surgeons with the unique ability to control the tension of the soft tissue repair. This product is a representation of our continued focus on providing valuable product innovation that supports surgeons and the patients they serve.”
The JuggerKnotless Soft Anchor features:
- The benefits of all-suture anchor technology, which eliminates the use of a hard implant that can fracture and cause loose bodies in the joint.
- A small, 2.1mm drill hole that preserves bone and allows more freedom in anchor placement.
- Unique technology that provides the surgeon with the ability to control the tension of the construct without tying a surgical knot.
The JuggerKnotless Soft Anchor will be featured at Biomet Sports Medicine’s booth #433 at the American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting in Seattle, WA July 10-12.
The JuggerKnotless Soft Anchor is cleared for use within the United States only. Distribution outside of the United States is prohibited.
Biomet is a manufacturer of orthopedic implants and does not practice medicine. Only an orthopedic surgeon can determine what treatment is appropriate. Individual results may vary. Potential risks include, but are not limited to, loosening, migration, wear, damage, or failure, any of which may require additional surgery. For additional information on the JuggerKnotless Soft Anchor, including risks and warnings, see the full patient risk information on Biomet.com.
All trademarks herein are the property of Biomet, Inc., or its subsidiaries, unless otherwise indicated.
Biomet, Inc. and its subsidiaries design, manufacture and market surgical and non-surgical products used primarily by orthopedic surgeons and other musculoskeletal medical specialists. Biomet's product portfolio includes hip and knee reconstructive products; sports medicine, extremities and trauma products; spine, bone healing and microfixation products; dental reconstructive products; and cement, biologics and other products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements are often indicated by the use of words such as “will,” “intend,” “anticipate,” “estimate,” “expect,” “plan” and similar expressions. Forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from those contemplated by the forward looking statements due to, among others, the following factors: the ability of the LVB Acquisition Inc. (“LVB”), the parent of Biomet, Inc. (the “Company”), and Zimmer Holdings, Inc. (“Zimmer”) to complete their proposed merger; LVB’s and Zimmer’s ability to obtain regulatory approvals of the proposed merger on the contemplated terms and schedule; the impact of the announcement of, or failure to complete, the proposed merger on relationships with distributors, employees, customers and suppliers; the success of the Company’s principal product lines; the results of the ongoing investigation by the United States Department of Justice; the ability to successfully implement new technologies; the Company’s ability to sustain sales and earnings growth; the Company’s success in achieving timely approval or clearance of its products with domestic and foreign regulatory entities; the impact to the business as a result of compliance with federal, state and foreign governmental regulations and with the Deferred Prosecution Agreement; the impact to the business as a result of the economic downturn in both foreign and domestic markets; the impact of federal health care reform; the impact of anticipated changes in the musculoskeletal industry and the ability of the Company to react to and capitalize on those changes; the ability of the Company to successfully implement its desired organizational changes and cost-saving initiatives; the ability of the Company to successfully integrate acquisitions; the impact to the business as a result of the Company’s significant international operations, including, among others, with respect to foreign currency fluctuations and the success of the Company’s transition of certain manufacturing operations to China; the impact of the Company’s managerial changes; the ability of the Company’s customers to receive adequate levels of reimbursement from third-party payors; the Company’s ability to maintain its existing intellectual property rights and obtain future intellectual property rights; the impact to the business as a result of cost containment efforts of group purchasing organizations; the Company’s ability to retain existing independent sales agents for its products; the impact of product liability litigation losses; and other factors set forth in the Company’s filings with the SEC, including the Company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although the Company believes that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance as to the accuracy of forward-looking statements contained in this press release. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company’s objectives will be achieved. The Company undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they were made.